^
    Back
    Association details:
    Biomarker:BRCA2 mutation + SPOP mutation
    Cancer:Prostate Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur Urol Oncol
    Title:

    Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

    Published date:
    12/11/2023
    Excerpt:
    ...PARP inhibitors appeared more effective in patients with BRCA2mut/SPOPmut than in patients with BRCA2mut/SPOPwt mCRPC.
    DOI:
    10.1016/j.euo.2023.11.014